A phase I/II trial of PXD101 [belinostat] in patients with unresectable hepatocellular carcinoma with pharmacokinetic and pharmacodynamic evaluation.
Phase of Trial: Phase I/II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Belinostat (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 18 Jan 2012 Results presented at the ASCO Gastrointestinal Cancers Symposium (ASCO-GCS)
- 13 Sep 2011 Status changed from recruiting to completed, according to results reported in a TopoTarget media release.
- 13 Sep 2011 Results reported in a TopoTarget media release, and will be presented at the 16th European Cancer Conference and the 36th Congress of the European Society for Medical Oncology.